Leap Therapeutics Inc (LPTX) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti

Leap Therapeutics Inc (LPTX) korporativ emblemasi va logotipi

Leap Therapeutics, Inc. (LPTX) narxlarni belgilash imkoniyatini saqlab qolish uchun eksklyuziv antitanachi huquqlaridan foydalangan holda, maqsadli onkologik davolash vositalarini ishlab chiqadi. Ishlab chiqish jarayoni klinik sinovlar bosqichlariga bog'liq bo'lgani sababli, biznes bozor tebranishlariga nisbatan barqaror qolmoqda. Biroq, logistik xavflar va Osiyodagi patent nizolari murakkabliklarni keltirib chiqarmoqda. -1.30 indikatori aks etgan ushbu narxlar grafigi kompaniya faoliyatining ushbu fundamental jihatlarini tasdiqlaydi.

LPTX leaptx.com: Narx-foyda koeffitsiyenti 04.07.2022 - 13.11.2025 oraligʻida

Leap Therapeutics, Inc. kompaniyasining tahliliy kesimlari

- bozor narxi va tahlilchilarning maqsadli narxlari:
Kompaniyaning har tomonlama tahlili:LPTX Leap Tx
Leap Therapeutics, Inc. ishlab chiqargan mahsulot

Investorlar Leap Therapeutics, Inc. (LPTX) bozor kapitalizatsiyasi va haqiqiy sof foyda o'rtasidagi bog'liqlikni baholash uchun P/E ko'rsatkichi grafigidan foydalanib, spekulyativ kutishlarni bartaraf etishlari kerak. Leap Therapeutics, Inc. (LPTX) onkologik dori vositalarini ishlab chiqishdan olinadigan litsenziya royalti to'lovlariga tayanganligi sababli, ushbu ko'rsatkich biznes qiymatini uning daromad keltirish fundamental qobiliyati bilan solishtirish imkonini beradi va vaqtincha bozor shov-shuvlaridan mustaqil bo'lgan adolatli aktiv baholashini aniqlaydi.

Raqobatdosh kompaniyalar

Kapitalizatsiyaning foydaga nisbati ImmunityBio IBRX|P/E multiplikatori IMCR|Janux Therapeutics (JANX) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Arcus Biosciences Inc - Narx-foyda koeffitsiyenti|Zymeworks (ZYME) - Kapitalizatsiyaning foydaga nisbati|TNGX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati IOVA (Iovance Biotherapeutics, Inc.)|IMTX: P/E multiplikatori|XNCR - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati compasstherapeutics.com|Narx-foyda koeffitsiyenti replimune.com (REPL)|Narxning foydaga nisbati Lyell (LYEL)|Narx-foyda koeffitsiyenti Innate Pharma, S.A. IPHA|Pyxis Oncology Inc. - Narx-foyda koeffitsiyenti|P/E multiplikatori Compugen Ltd. CGEN|IOBT - Narxning foydaga nisbati|STRO (sutrobio.com) - Narx-foyda multiplikatori|MiNK Therapeutics, Inc (INKT) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Werewolf Therapeutics (HOWL)|Narx-foyda koeffitsiyenti IMMX|ALXO - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|P/E multiplikatori CUE|Bozor narxining sof foydaga nisbati PDSB|P/E multiplikatori SONN (Sonnet BioTherapeutics)|Kompaniya qiymatining sof foydaga nisbati MAIA|liminatuspharma.com - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati LAVA Therapeutics|NextCure, Inc. (NXTC) - Narxning foydaga nisbati|Intensity Therapeutics Inc - Kompaniya qiymatining sof foydaga nisbati|SNSE (Sensei Bio) - P/E multiplikatori|P/E multiplikatori Theriva Biologics Inc|Narxning foydaga nisbati gritstonebio.com (GRTS)|P/E multiplikatori Kineta Bio (KA)|NexImmune Inc - Narx-foyda koeffitsiyenti|turnstonebio.com (TSBX) - Kapitalizatsiyaning foydaga nisbati|VCNX: Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati HARP (Harpoon Therapeutics, Inc.)